The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes.
The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes. Pregnant women undergoing specialized fetal anatomic ultrasound surveys at Women and Infants' maternal fetal medicine prenatal diagnostic imaging centers will be recruited to participate. Volunteers will be randomized to receive either standard education about prenatal genetic testing or standard education plus additional education about federal genetic privacy protections. Next, the participants view the educational materials to which they were randomized. Finally, all volunteers will take the same survey, which will assess baseline demographic variables as well as their knowledge of and attitudes toward broad sharing of data obtained from prenatal genetic testing. Once finished with the survey, volunteers will have completed their participation in this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
162
See arm description.
See arm description.
Women and Infants Hospital
Providence, Rhode Island, United States
Knowledge about broad sharing of genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient knowledge about the potential sharing of their genetic data for non-clinical research purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of broad sharing of genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of laboratory-initiated sharing of their de-identified genetic data for non-clinical purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of retention of genetic data for non-clinical purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of retaining their de-identified genetic data to potentially use it for non-clinical purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of use of genetic data for non-clinical purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of using their de-identified genetic data for non-clinical purposes such as research and development? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Knowledge and understanding of aneuploidy screening and results
Are patients aware that they underwent aneuploidy screening with cell-free fetal DNA (cfDNA)? Are they aware of their results? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Knowledge and understanding of carrier testing and results
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patients aware that they underwent carrier testing? Are they aware of their results? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of retention, use, and broad sharing of fetal genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Assess maternal acceptance of each of these outcomes. Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal rationale for pursuing cfDNA
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What prompted patient to pursue cfDNA testing? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal knowledge of different commercial cfDNA providers
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patents who have undergone cfDNA testing aware that multiple companies offer this service? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal knowledge pertaining to Down Syndrome and the genetics of trisomies.
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening and are participating in this study understand these topics? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal perceptions of the de-identifiability of genetic data
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening believe that deidentified genetic information is not re-identifiable? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)